By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Lux Biosciences 

New York City  New York    U.S.A.
Phone: 917-518-2875 Fax:



Start Up

Company News
Isotechnika Pharma Inc. (ISA.TO) Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint 12/27/2012 8:44:57 AM
Isotechnika Pharma Inc. (ISA.TO)'s Partner Lux Biosciences Completes Enrollment in Phase 3 Uveitis Study 7/9/2012 9:09:10 AM
Lux Biosciences Receives Complete Response Letter from FDA for Luveniq(TM) 8/4/2010 12:19:56 PM
Lux Biosciences, Isotechnika Pharma Inc. (ISA.TO) Receive Complete Response Letter from FDA for Voclosporin; FDA Requests Additional Information and Clinical Trial; Isotechnika Shares Dive 32.56% at 1:22PM EDT 8/4/2010 7:46:15 AM
Lux Biosciences Names Dean Mitchell President and CEO 7/1/2010 6:59:27 AM
FDA Cancels Advisory Committee Meeting for Coclosporin; Priority Review of Lux Biosciences' NDA Continues 6/23/2010 7:28:35 AM
Lux Biosciences' Luveniq Receives FDA Priority Review 3/30/2010 7:01:33 AM
Lux Biosciences Receives Acceptance of Luveniq(TM) MAA Filing from European Medicines Evaluation Agency 3/2/2010 11:04:16 AM
Lux Biosciences Files for LUVENIQ(TM) Approval in US and Europe for Noninfectious Uveitis 2/4/2010 10:44:45 AM
Lux Biosciences to Present at Lazard Capital Markets 6th Annual Healthcare Conference 11/16/2009 9:34:46 AM